Status:
UNKNOWN
Pilot Study: hCG Secreted by Blastocyst as Potential Marker of Embryo Quality
Lead Sponsor:
IVI Vigo
Collaborating Sponsors:
Instituto Valenciano de Infertilidad, IVI VALENCIA
Conditions:
Embryo Disorder
Eligibility:
FEMALE
18-41 years
Brief Summary
hCG is a hormone produced very early by the pre-embryo, but not by the oocyte. It has a pivotal role in the trophoblast differentiation, and embryo implantation as well as the corpus luteum support. I...
Detailed Description
Embryo selection based on morphological and morphokinetic characteristics seems to be insufficient to guarantee implantation. For this reason, in recent years, it has appeared new embryo selection str...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age \< 42.
- BMI \< 30kg/m2.
- SET (Single embryo transfer)
- Exclusion Criteria:
- Hydrosalpinx.
- Any indication of oocyte vitrification
Exclusion
Key Trial Info
Start Date :
December 5 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 25 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04736160
Start Date
December 5 2018
End Date
November 25 2021
Last Update
February 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IVI Vigo
Vigo, Pontevedra, Spain, 36203